Short description
Eidos Therapeutics is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients.
Description
BridgeBio is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients. The BridgeBio approach combines a traditional focus on drug development with a unique corporate model, allowing rapid translation of early stage science into medicines that treat disease at its source.
Last funding
Noaccessforu
Sign in for full access
Total funding
$$3123123
Sign in for full access
Location
Palo Alto, California, United States, North America
Founded on
August 1, 2013
Exited on
June 20, 2018
Went public on
June 20, 2018
Delisted on
January 26, 2021
Stock symbol
EIDX
Non-profit?
No
Acquired?
No
Employees count
51-100
Revenue range
$56378 - 90123
Sign in for full access
Investors
Noaccessforu, Uh Ohhhh, Blurry Noaccess, Noaccessforu, Noaccessforu, Cannot Access, Nopepepe, Cannot Access
Sign in for full access
Founders
Isabella Graef, Mamoun Alhamadsheh